Management site and level of health care for cannabis- and synthetic cannabinoid-related poison control center cases involving older adults, 2016–2019

References

• Adams, M.L., 2017. Differences between younger and older US adults with multiple chronic conditions. Preventing Chronic Disease, 14, E76.
   PubMed Web of Science ®Google Scholar
• Allison, P., 2012. Statistical Horizons. When can you safely ignore multicollinearity? Accessed at: https://statisticalhorizons.com/multicollinearity.
   Google Scholar
• Aviram, J., and Samuelly-Leichtag, G., 2017. Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain. Physician, 20 (6), E755–E796.
   PubMed Web of Science ®Google Scholar
• Bass, J., and Linz, D.R., 2020. A case of toxicity from cannabidiol gummy ingestion. Cureus, 12 (4), e7688.
   PubMed Web of Science ®Google Scholar
• Bobitt, J., et al., 2019. Qualitative analysis of cannabis use among older adults in Colorado. Drugs & Aging, 36 (7), 655–666.
   PubMed Web of Science ®Google Scholar
• Bonomo, Y., et al., 2018. Clinical issues in cannabis use. British Journal of Clinical Pharmacology, 84 (11), 2495–2498.
   PubMed Web of Science ®Google Scholar
• Brown, J.D., et al., 2020. Characteristics of older adults who were early adopters of medical cannabis in the Florida medical marijuana use registry. Journal of Clinical Medicine, 9 (4), 1166.
   Web of Science ®Google Scholar
• Bush, D. M., and Woodwell, D. A., 2013. Update: Drug-related emergency department visits involving synthetic cannabinoids. In: The CBHSQ Report. Rockville, MD: Substance Abuse and Mental Health Services Administration (US), 1–10.
   Google Scholar
• Calcaterra, S.L., et al., 2019. Changes in healthcare encounter rates possibly related to cannabis or alcohol following legalization of recreational marijuana in a safety-net hospital: An interrupted time series analysis. Journal of Addiction Medicine, 13 (3), 201–208.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Outbreak of lung injury associated with the use of e-cigarette, or vaping, products. 2020, February 25. Accessed at: https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html
   Google Scholar
• Choi, N.G., DiNitto, D.M., and Choi, B.Y., 2021. Prescription pain reliever use and misuse among cannabis users aged 50+ years. Clinical Gerontologist, 44 (1), 53–65.
   PubMed Web of Science ®Google Scholar
• Choi, N.G., DiNitto, D.M., and Marti, C.N., 2016. Older-adult marijuana users and ex-users: comparisons of sociodemographic characteristics and mental and substance use disorders. Drug and Alcohol Dependence, 165, 94–102.
   PubMed Web of Science ®Google Scholar
• Choi, N.G., DiNitto, D.M., and Marti, C.N., 2017. Nonmedical versus medical marijuana use among three age groups of adults: associations with mental and physical health status. The American Journal on Addictions, 26 (7), 697–706.
   PubMed Web of Science ®Google Scholar
• Choi, N.G., DiNitto, D.M., and Marti, C.N., 2018. Older marijuana users' marijuana risk perceptions: associations with marijuana use patterns and marijuana and other substance use disorders. International Psychogeriatrics, 30 (9), 1311–1322.
   PubMed Web of Science ®Google Scholar
• Cohen, K., Weizman, A., and Weinstein, A., 2019. Positive and negative effects of cannabis and cannabinoids on health. Clinical Pharmacology and Therapeutics, 105 (5), 1139–1147.
   PubMed Web of Science ®Google Scholar
• Compton, R., 2017. July. Marijuana-impaired driving - A report to Congress. (DOT HS 812 440). Washington, DC: National Highway Traffic Safety Administration. Accessed at: https://rosap.ntl.bts.gov/view/dot/34995
   Google Scholar
• DISA. 2020. Map of marijuana legality by state. Accessed at: https://disa.com/map-of-marijuana-legality-by-state.
   Google Scholar
• Giombi, K.C., et al., 2018. Consumers' perceptions of edible marijuana products for recreational use: likes, dislikes, and reasons for use. Substance Use and Misuse, 53 (4), 541–547.
   PubMed Web of Science ®Google Scholar
• Gummin, D.D., et al., 2019. 2018 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 36th Annual Report. Clinical Toxicology (Philadelphia, Pa.).), 57 (12), 1220–1413.
   PubMed Web of Science ®Google Scholar
• Hall, K.E., et al., 2018. Mental health-related emergency department visits associated with cannabis in Colorado. Academic Emergency Medicine, 25 (5), 526–537.
   PubMed Web of Science ®Google Scholar
• Hall, W., et al., 2019. Public health implications of legalising the production and sale of cannabis for medicinal and recreational use. Lancet (London, England), 394 (10208), 1580–1590.
   PubMed Web of Science ®Google Scholar
• Hasin, D.S., 2018. US Epidemiology of cannabis use and associated problems. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 43 (1), 195–212.
   PubMed Web of Science ®Google Scholar
• Häuser, W., Petzke, F., and Fitzcharles, M.A., 2018. Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management - An overview of systematic reviews. European Journal of Pain (London, England)), 22 (3), 455–470.
   PubMed Web of Science ®Google Scholar
• Joseph, A., et al., 2019. A polydrug and psychosocial profile of synthetic cannabinoid use in a New York City community sample, 2016-2017. Substance Use and Misuse, 54 (2), 282–287.
   PubMed Web of Science ®Google Scholar
• Jouanjus, E., Lapeyre-Mestre, M., and Micallef, J, French Association of the Regional Abuse and Dependence Monitoring Centres (CEIP-A) Working Group on Cannabis Complications 2014. Cannabis use: signal of increasing risk of serious cardiovascular disorders. Journal of the American Heart Association, 3 (2), e000638.
   PubMed Web of Science ®Google Scholar
• Kim, J., and Parish, A.L., 2017. Polypharmacy and medication management in older adults. Nursing Clinics of North America, 52 (3), 457–468.
   PubMed Web of Science ®Google Scholar
• Lau, N., et al., 2015. Responsible and controlled use: Older cannabis users and harm reduction. The International Journal on Drug Policy, 26 (8), 709–718.
   PubMed Web of Science ®Google Scholar
• Law, R., et al., Centers for Disease Control (CDC) 2015. Notes from the field: Increase in reported adverse health effects related to synthetic cannabinoid use - United States, January-May 2015. MMWR. Morbidity and Mortality Weekly Report, 64 (22), 618–619.
   PubMed Web of Science ®Google Scholar
• Lum, H.D., et al., 2019. Patterns of marijuana use and health impact: a survey among older Coloradans. Gerontology and Geriatric Medicine, 5, 2333721419843707.
   Web of Science ®Google Scholar
• Monte, A.A., et al., 2019. Acute illness associated with cannabis use, by route of exposure: an observational study. Annals of Internal Medicine, 170 (8), 531–537.
   PubMed Web of Science ®Google Scholar
• Mücke, M., et al., 2018. Cannabis-based medicines for chronic neuropathic pain in adults. The Cochrane Database of Systematic Reviews, 3 (3), CD012182.
   PubMedGoogle Scholar
• National Academies of Sciences, Engineering, and Medicine. 2017. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington, DC: The National Academies Press. .
   Google Scholar
• Navon, L., et al., 2019. Risk factors for e-cigarette, or vaping, product use-associated lung injury (EVALI) among adults who use e-cigarette, or vaping, products - Illinois, July-October 2019. MMWR Morbidity and Mortality Weekly Report, 68 (45), 1034–1039.
   PubMed Web of Science ®Google Scholar
• Nourbakhsh, M., et al., 2019. Cannabinoid hyperemesis syndrome: reports of fatal cases. Journal of Forensic Sciences, 64 (1), 270–274.
   PubMed Web of Science ®Google Scholar
• Orsini, J., et al., 2015. The wide and unpredictable scope of synthetic cannabinoids toxicity. Case Reports in Critical Care, 2015, 542490.
   PubMedGoogle Scholar
• Page, R.L. 2nd, Allen, L.A., Kloner, R.A., et al.,; American Heart Association Clinical Pharmacology Committee and Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; Council on Lifestyle and Cardiometabolic Health; and Council on Quality of Care and Outcomes Research. 2020. Medical marijuana, recreational cannabis, and cardiovascular health: a scientific statement from the American Heart Association. Circulation, 142 (10), e131–e152.
   PubMed Web of Science ®Google Scholar
• Pratt, M., et al., 2019. Benefits and harms of medical cannabis: a scoping review of systematic reviews. Systematic Reviews, 8 (1), 320.
   PubMed Web of Science ®Google Scholar
• Reynolds, I.R., et al., 2018. Characteristics and patterns of marijuana use in community-dwelling older adults. Journal of the American Geriatrics Society, 66 (11), 2167–2171.
   PubMed Web of Science ®Google Scholar
• Rezkalla, S., and Kloner, R.A., 2019. Cardiovascular effects of marijuana. Trends Cardiovasc Med, 29 (7), 403–407.
   PubMed Web of Science ®Google Scholar
• Roberts, B.A., 2019. Legalized cannabis in Colorado emergency departments: a cautionary review of negative health and safety effects. The Western Journal of Emergency Medicine, 20 (4), 557–572.
   PubMed Web of Science ®Google Scholar
• Roehler, D.R., Hoots, B.E., and Vivolo-Kantor, A.M., 2020. Regional trends in suspected synthetic cannabinoid exposure from January 2016 to September 2019 in the United States. Drug and Alcohol Dependence, 207, 107810.
   PubMed Web of Science ®Google Scholar
• Rowley, E., et al., 2017. Clinical and financial implications of emergency department visits for synthetic marijuana. American Journal of Emergency Medicine, 35 (10), 1506–1509.
   PubMed Web of Science ®Google Scholar
• Shelton, S.K., et al., 2020. Why do patients come to the emergency department after using cannabis? Clinical Toxicology, 58 (6), 453–459.
   PubMed Web of Science ®Google Scholar
• U.S. Drug Enforcement Administration. 2011. Schedules of Controlled Substances: Temporary Placement of Five Synthetic Cannabinoids Into Schedule I. 2011, February 18. Accessed at: https://www.deadiversion.usdoj.gov/fed_regs/rules/2011/fr0301.htm.
   Google Scholar
• U.S. Food and Drug Administration. 2020. FDA regulation of cannabis and cannabis-derived products including cannabidiol (CBD). 2020, March 11. Accessed at: https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd#approved
   Google Scholar
• Wang, G.S., et al., 2017. Marijuana and acute health care contacts in Colorado. Preventive Medicine, 104, 24–30.
   PubMed Web of Science ®Google Scholar
• Winnicka, L., and Shenoy, M.A., 2020. EVALI and the pulmonary toxicity of electronic cigarettes: a review. Journal of General Internal Medicine, 35 (7), 2130–2135.
   PubMed Web of Science ®Google Scholar